What is the 13F Pro Quality Score for ESTA?

13F Pro ranks ESTABLISHMENT LABS HOLDINGS INC. (ESTA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ESTA's current score at https://13fpro.ai/research/ESTA (free sign-up required for the full ranking).

Which hedge funds own the most ESTA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ESTA include JW Asset Management,, RTW INVESTMENTS,, BROWN ADVISORY. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ESTA as soon as new 13F filings post.

Where does 13F Pro source ESTA data?

All ESTABLISHMENT LABS HOLDINGS INC. fundamentals and ownership data come directly from SEC EDGAR. ESTABLISHMENT LABS HOLDINGS INC. files with the SEC under CIK 1688757. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ESTA in?

ESTABLISHMENT LABS HOLDINGS INC. (ESTA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ESTA research updated on 13F Pro?

ESTA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ESTABLISHMENT LABS HOLDINGS INC.(ESTA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1688757 ESTA stock profile & AI dashboard →

13F Pro Quality Score

26.7/100

Rank #2,495 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

65.2/100

Profitability

15.2/100

Balance Sheet

12.9/100

Earnings Quality

30.0/100

Free Cash Flow

11.6/100

Institutional Flow

9.2/100

Revenue Scale

24.8/100

Dilution Risk

24.6/100

ESTA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ESTABLISHMENT LABS HOLDINGS INC. (ESTA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ESTA at 26.7/100 on a 32-signal composite quality model, placing it at rank #2,495 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (9.2) and free cash flow (11.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ESTABLISHMENT LABS HOLDINGS INC. reports quarterly revenue of $59.9M, net income of $-13.4M, free cash flow of $-6.2M. Top institutional holders of ESTA by reported 13-F value include JW Asset Management,, RTW INVESTMENTS,, BROWN ADVISORY, based on the most recent SEC filings. ESTA trades on the Nasdaq exchange and files with the SEC under CIK 1688757. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ESTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ESTABLISHMENT LABS HOLDINGS INC. directly from SEC EDGAR. ESTABLISHMENT LABS HOLDINGS INC.'s 13F Pro composite quality score has ranged between 21 and 34 since 2021, currently 26.7 — a declining long-term trajectory across 25 quarterly and live scoring snapshots.

✦

Fun facts about ESTABLISHMENT LABS HOLDINGS INC.

Quirks, history, and lore behind ESTA — the kind of stuff that makes a stock memorable.

1
The Basics
A medical device company · small-cap · listed on Nasdaq · headquartered in Costa Rica with U.S. offices in California.
2
The Numbers
Annual revenue in the range of $200–300 million — modest by med-device standards — but growing fast in a market that's billions of dollars and largely recession-proof.
3
The History
Founded in the 2010s, it set out to challenge the two giants that had long dominated breast implant surgery with a next-generation device and a data-driven approach.
4
The Secret
Its flagship implant is built around a proprietary gel matrix technology designed to feel more natural and reduce the rupture and rippling complaints that haunted older products.
5
The Lore
The company bets heavily on surgeon education and outcomes tracking, running a global registry so it can actually prove — with real-world data — that its implants perform better.
6
The Giveaway
Its Motiva breast implant line is sold in over 80 countries, and the whole company exists to convince plastic surgeons that the incumbents' decades-old designs deserve to be disrupted.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$59.9M

Net Income

Q1 2026

$-13.4M

Free Cash Flow

Q1 2026

$-6.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+27.1% YoY

$211.1MFY 2025

FY21 $126.7MFY23 $165.2MFY24 $166.0MFY25 $211.1M

Net Income

+39.6% YoY

$-51.1MFY 2025

FY21 $-41.1MFY23 $-78.5MFY24 $-84.6MFY25 $-51.1M

Operating Income

+22.0% YoY

$-39.0MFY 2025

FY21 $-25.1MFY23 $-65.0MFY24 $-50.0MFY25 $-39.0M

EPS (Diluted)

+42.7% YoY

$-1.72FY 2025

FY21 $-1.72FY23 $-3.07FY24 $-3.00FY25 $-1.72

Total Assets

+3.0% YoY

$357.2MFY 2025

FY21 $139.5MFY23 $268.6MFY24 $346.8MFY25 $357.2M

Total Debt

+12.7% YoY

$247.5MFY 2025

FY21 $51.9MFY23 $188.7MFY24 $219.6MFY25 $247.5M

Op. Cash Flow

+13.0% YoY

$-50.9MFY 2025

FY21 $-27.5MFY23 $-88.5MFY24 $-58.5MFY25 $-50.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2019	FY 2017
Revenue	$211.1M +27.1%	$166.0M +0.5%	$165.2M +30.4%	$126.7M +41.4%	$89.6M +158.3%	$34.7M
Net Income	$-51.1M +39.6%	$-84.6M -7.8%	$-78.5M -90.8%	$-41.1M -7.8%	$-38.1M -9.3%	$-34.9M
Operating Income	$-39.0M +22.0%	$-50.0M +23.1%	$-65.0M -158.7%	$-25.1M +18.7%	$-30.9M -54.8%	$-20.0M
EPS (Diluted)	$-1.72 +42.7%	$-3.00 +2.3%	$-3.07 -78.5%	$-1.72 +7.5%	$-1.86	—
Total Assets	$357.2M +3.0%	$346.8M +29.1%	$268.6M +92.5%	$139.5M +19.7%	$116.5M +104.1%	$57.1M
Total Debt	$247.5M +12.7%	$219.6M +16.3%	$188.7M +263.6%	$51.9M +7.8%	$48.1M	—
Operating Cash Flow	$-50.9M +13.0%	$-58.5M +33.9%	$-88.5M -221.5%	$-27.5M +8.2%	$-30.0M +6.2%	$-32.0M

AI Insight: ESTA Financial Trends

Revenue has grown 36% from Q2 2024 to Q4 2025 and operating losses are narrowing, but rising debt and shrinking equity signal mounting balance-sheet stress.

• Revenue grew from $44M in Q2 2024 to $65M in Q4 2025, a 48% increase, though Q1 2026 pulled back to $60M.

• Operating loss narrowed sharply from -$19M in Q4 2024 to -$4M in Q4 2025, suggesting improving operational efficiency.

• Total debt rose from $194M in Q2 2024 to $249M in Q1 2026, a $55M increase over six quarters.

• Equity collapsed from $45M in Q2 2024 to $15M in Q1 2026, reflecting sustained net losses eroding the book value.

⚠ Operating CF improved to nearly breakeven -$0M in Q4 2025 but deteriorated back to -$4M in Q1 2026 — trend sustainability is uncertain.

⚠ Equity at $15M against $249M debt implies near-zero book cushion; further losses could push equity negative.

⚠ Net loss widened from -$3M in Q4 2025 to -$13M in Q1 2026 — first sequential worsening after four quarters of improvement.

AI Insight: ESTA Ratio Trends

Operating losses are narrowing sharply from a -41.9% trough in Q4 2024, but surging D/E of 16.82 signals the recovery is debt-funded.

• Operating margin improved dramatically from -41.9% in Q4 2024 to -6.1% in Q4 2025, the best quarterly reading in the dataset.

• Net profit margin swung from -77.6% in Q4 2024 to -4.0% in Q4 2025, suggesting meaningful cost discipline or one-off relief.

• D/E ratio has surged from 4.14 in Q4 2024 to 16.82 in the TTM period, indicating heavy reliance on debt to fund operations.

• ROIC remains negative across all periods, ranging from -5.8% in Q4 2025 to -27.4% in Q4 2024, with no positive inflection yet.

⚠ Q1 2026 operating margin deteriorated to -10.9% from Q4 2025's -6.1%, raising concern the Q4 2025 improvement may not persist.

⚠ D/E at 16.82 is the highest in the dataset; monitor whether rising interest burden further pressures already-negative net margins.

⚠ ROE data is largely missing; a return to positive ROE would be a key milestone confirming the profitability recovery is durable.

Get alerted when ESTA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ESTABLISHMENT LABS HOLDINGS INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ESTA

JW Asset Management, LLC
$173.8M3,061,694 sh
RTW INVESTMENTS, LP
$150.8M2,655,695 sh
BROWN ADVISORY INC
$86.7M1,526,872 sh
Tyro Capital Management LLC
$71.0M1,250,000 sh
Tyro Capital Management LLC
$65.4M1,151,309 sh
FINDELL CAPITAL MANAGEMENT LLC
$56.7M997,747 sh
BAMCO INC /NY/
$54.7M964,167 sh
Nantahala Capital Management, LLC
$47.3M832,956 sh
Mudita Advisors LLP
$43.4M764,563 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$39.6M696,800 sh

Fund	Value	Shares
JW Asset Management, LLC	$173.8M	3,061,694
RTW INVESTMENTS, LP	$150.8M	2,655,695
BROWN ADVISORY INC	$86.7M	1,526,872
Tyro Capital Management LLC	$71.0M	1,250,000
Tyro Capital Management LLC	$65.4M	1,151,309
FINDELL CAPITAL MANAGEMENT LLC	$56.7M	997,747
BAMCO INC /NY/	$54.7M	964,167
Nantahala Capital Management, LLC	$47.3M	832,956
Mudita Advisors LLP	$43.4M	764,563
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$39.6M	696,800

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ESTA on your watchlist

Track score changes the day ESTABLISHMENT LABS HOLDINGS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ESTA a good stock to buy?

13F Pro's AI-powered analysis of ESTABLISHMENT LABS HOLDINGS INC. (ESTA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ESTA are available on the ESTA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ESTA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ESTA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ESTABLISHMENT LABS HOLDINGS INC.'s investment landscape.